James joined the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) as Executive Director of Global Health in January 2021, where he is responsible for leading the delivery of IFPMA’s relevant policy and advocacy work. In his previous role as Head of Corporate Government Affairs at GSK, James led engagement with the UK Government spanning GSK’s pharmaceuticals, vaccines, and consumer businesses. James was a member of the UK Government’s Life Science Strategy Board and Vice-Chair of Business at OECD’s Healthcare Committee. James also led GSK’s strategy and advocacy on Antimicrobial Resistance (AMR). He advised on AMR policy development at the WHO, UN, EU Commission, the O’Neill Review and National Governments. He was Chair of the Industry AMR Committee, in the Founding team of the AMR Action Fund and led the development of the Davos Declaration and 2016 UNGA Industry AMR Roadmap.